Top

Journal of Ophthalmic Inflammation and Infection

Published in:

Open Access 01-12-2024 | Conjunctivitis | Brief Report

Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease

Authors: Nenita Maganti, Samuel A. Whittier, Evan J. Warner

Published in: Journal of Ophthalmic Inflammation and Infection | Issue 1/2024

Abstract

Background

Dupilumab and tralokinumab are interleukin-binding monoclonal antibodies used to treat systemic atopic disease. Use of these medications in management of atopic dermatitis (AD) is known to cause conjunctivitis. Dupilumab therapy has also been associated with more severe ocular surface disease, which has not previously been described in association with tralokinumab. This report describes a case of tralokinumab-associated conjunctivitis and peripheral ulcerative keratitis and reviews the spectrum and proposed mechanisms of ocular surface disease triggered by these medications.

Case presentation

A 61-year-old male with no rheumatologic or ocular history presented with bilateral papillary conjunctivitis and right eye peripheral ulcerative keratitis (PUK). PUK was arrested using oral corticosteroids and doxycycline, and long-term control of papillary conjunctivitis was achieved using topical tacrolimus ointment, allowing continuation of effective AD management with tralokinumab.

Conclusion

This case report documents ulcerative keratitis occurring in association with tralokinumab therapy for AD, which has previously been described with dupilumab but not tralokinumab. This report demonstrates the need for vigilant ocular surface monitoring for patients on tralokinumab and illustrates successful management and long-term control of adverse ocular events associated with this medication.

Mickevicius T, Pink AE, Bhogal M, O’Brart D, Robbie SJ, Dupilumab-Induced (2023) Tralokinumab-Induced, and Belantamab Mafodotin-Induced adverse ocular Events-Incidence, etiology, and management. Cornea 42(4):507–519CrossRefPubMed

Phylactou M, Jabbour S, Ahmad S, Vasquez-Perez A (2022) Corneal perforation in patients under treatment with Dupilumab for atopic dermatitis. Cornea 41(8):981–985CrossRefPubMed

Simpson EL, Merola JF, Silverberg JI et al (2022) Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol 187(6):888–899CrossRefPubMedPubMedCentral

Popiela MZ, Barbara R, Turnbull AMJ et al (2021) Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond) 35(12):3277–3284CrossRefPubMed

Ivert LU, Wahlgren CF, Ivert L, Lundqvist M, Bradley M (2019) Eye complications during Dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol 99(4):375–378CrossRefPubMed

Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA (2020) Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol 104(6):776–779CrossRefPubMed

Akinlade B, Guttman-Yassky E, de Bruin-Weller M et al (2019) Conjunctivitis in dupilumab clinical trials. Br J Dermatol 181(3):459–473CrossRefPubMedPubMedCentral

Bohner A, Topham C, Strunck J et al (2021) Dupilumab-Associated Ocular Surface Disease: clinical characteristics, treatment, and Follow-Up. Cornea 40(5):584–589CrossRefPubMedPubMedCentral

Far PM, Quinn MP, Johnson D (2022) Bilateral Peripheral Ulcerative Keratitis Associated with Dupilumab. Ophthalmology 129(5):561CrossRefPubMed

10.

Asher MI, Montefort S, Björkstén B et al (2007) Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys [published correction appears in Lancet. ;370(9593):1128]. Lancet. 2006;368(9537):733–743

11.

Williams H, Robertson C, Stewart A et al (1999) Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and allergies in Childhood. J Allergy Clin Immunol 103(1 Pt 1):125–138CrossRefPubMed

12.

Mayba JN, Gooderham MJ (2017) Review of atopic dermatitis and topical therapies. J Cutan Med Surg 21(3):227–236CrossRefPubMed

13.

Dana MR, Qian Y, Hamrah P (2000) Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 19(5):625–643CrossRefPubMed

14.

Hassanpour K, ElSheikh H, Arabi R (2022) Peripheral ulcerative keratitis: a review. J Ophthalmic Vis Res 17(2):252–275PubMedPubMedCentral

15.

Gupta Y, Kishore A, Kumari P et al (2021) Peripheral ulcerative keratitis. Surv Ophthalmol 66(6):977–998CrossRefPubMed

16.

Gomes BF, Santhiago MR (2021) Biology of peripheral ulcerative keratitis. Exp Eye Res 204:108458CrossRefPubMed

17.

Clarke D, Sartor L, Do V, Manolios N, Swaminathan S, Samarawickrama C (2023) Biologics in peripheral ulcerative keratitis. Semin Arthritis Rheum 63:152269CrossRefPubMed

18.

Treister AD, Kraff-Cooper C, Lio PA (2018) Risk factors for Dupilumab-Associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 154(10):1208–1211CrossRefPubMedPubMedCentral

19.

Tauber J, de la Sainz M, Hoang-Xuan T, Foster CS (1990) An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea 9(1):66–73CrossRefPubMed

20.

Blauvelt A, de Bruin-Weller M, Gooderham M et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287–2303CrossRefPubMed

21.

Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of Dupilumab versus Placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348CrossRefPubMed

22.

Wollenberg A, Howell MD, Guttman-Yassky E et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 143(1):135–141CrossRefPubMed

23.

Wollenberg A, Blauvelt A, Guttman-Yassky E et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437–449CrossRefPubMed

24.

Silverberg JI, Toth D, Bieber T et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184(3):450–463CrossRefPubMedPubMedCentral

25.

Liberman P, Shifera AS, Berkenstock M (2020) Dupilumab-Associated conjunctivitis in patients with atopic dermatitis. Cornea 39(6):784–786CrossRefPubMed

26.

Levine RM, Tattersall IW, Gaudio PA, King BA (2018) Cicatrizing Blepharoconjunctivitis Occurring during Dupilumab Treatment and a proposed algorithm for its management. JAMA Dermatol 154(12):1485–1486CrossRefPubMed

27.

Lee DH, Cohen LM, Yoon MK, Tao JP (2021) Punctal stenosis associated with dupilumab therapy for atopic dermatitis. J Dermatolog Treat 32(7):737–740CrossRefPubMed

28.

Li G, Berkenstock M, Soiberman U (2020) Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis. Am J Ophthalmol Case Rep 19:100848CrossRefPubMedPubMedCentral

29.

Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA (2020) Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients’ records. Int J Dermatol 59(2):253–256CrossRefPubMed

30.

Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC (2019) Ocular Surface diseases Induced by Dupilumab in severe atopic dermatitis. Ophthalmol Ther 8(3):485–490CrossRefPubMedPubMedCentral

31.

Barnett BP, Afshari NA (2020) Dupilumab-Associated Mucin Deficiency (DAMD) [published correction appears in Transl Vis Sci Technol. ;9(8):21]. Transl Vis Sci Technol. 2020;9(3):29

32.

Bakker DS, Ariens LFM, van Luijk C et al (2019) Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 180(5):1248–1249CrossRefPubMedPubMedCentral

33.

Calabrese G, Gambardella A, Licata G, Di Brizzi EV, Alfano R, Argenziano G (2021) Dupilumab and conjunctivitis: a case series of twenty patients. J Eur Acad Dermatol Venereol 35(9):e612–e614CrossRefPubMed

34.

Fukuda K, Ishida W, Kishimoto T, Fukushima A (2019) Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int 68(3):383–384CrossRefPubMed

35.

Roca-Ginés J, Rahhal-Ortuño M, Torres-Navarro I, Rodríguez-Serna M, Navarro-Mira MÁ (2019) Cyclosporine 0.1% (Ikervis^®) treatment in steroid-dependent dupilumab-associated conjunctivitis. Arch Soc Esp Oftalmol (Engl Ed) 94(8):396–399CrossRefPubMed

36.

Frazier W, Bhardwaj N (2020) Atopic dermatitis: diagnosis and treatment. Am Fam Physician 101(10):590–598PubMed

37.

Francuzik W, Alexiou A, Worm M (2021) Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf 20(9):997–1004CrossRefPubMed

Title: Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease
Authors: Nenita Maganti
Samuel A. Whittier
Evan J. Warner
Publication date: 01-12-2024
Publisher: Springer Berlin Heidelberg
Keywords: Conjunctivitis
Dupilumab
Atopic Dermatitis
Published in: Journal of Ophthalmic Inflammation and Infection / Issue 1/2024
Electronic ISSN: 1869-5760
DOI: https://doi.org/10.1186/s12348-024-00394-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease

Abstract

Background

Case presentation

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Long-term follow-up of a bilateral acute posterior multifocal placoid pigment epitheliopathy following COVID-19 infection: a case report

Clinical analysis of infectious endophthalmitis following glaucoma filtration surgery

Three cases of recalcitrant Paecilomyces keratitis in Southern California within a short period

Comparing the in vitro efficacy of chlorhexidine and povidone-iodine in the prevention of post-surgical endophthalmitis

Prognostic indicators of corneal ulcer clinical outcomes at a tertiary care center in the Bronx, New York

Piloting Rasch model scoring of the National Eye Institute Visual Function Questionnaire in uveitis